

## PRESS RELEASE

innate pharma

### UPCOMING INVESTOR CONFERENCES

#### Marseille, France, April 28, 2016

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the second quarter of 2016:

- **Gilbert Dupont Healthcare Conference** – Paris, May 10, 2016
- **Citi Swiss Healthcare Investor Day** – Zurich, May 19-20, 2016
- **Goldman Sachs 37<sup>th</sup> Annual Global Healthcare Conference** – Rancho Palos Verdes, June 7-9, 2016
- **Kepler Cheuvreux Biotech Days Conference** – Paris, June 15-16, 2016
- **Bryan Garnier 1<sup>st</sup> Oncology Day** – Paris, June 17, 2016
- **Citi European Healthcare Conference** – London, June 21-22, 2016
- **Société Générale CIB Healthcare & Biotechnology Conference** – Paris, June 28, 2016

\*\*\*\*\*


The Company will host an  
**Investor & Analyst Update on May 16th, 2016**,  
in New York, USA, from 12:00 to 3:00 pm ET.

Innate Pharma's management team will give an overview of the Company's pipeline of first-in-class monoclonal antibodies in Immuno-Oncology and provide an update on the Company's strategy.

*The event is intended for institutional investors and sell-side analysts only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at [mac@lifesciadvisors.com](mailto:mac@lifesciadvisors.com).*

\*\*\*\*\*

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section ([www.innate-pharma.com/en/financials](http://www.innate-pharma.com/en/financials)).



## PRESS RELEASE

innate pharma

---

### About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.

The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.

Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and AstraZeneca, Sanofi and Novo Nordisk A/S.

Based in Marseille, France, Innate Pharma had 118 employees as at December 31, 2015. The company is listed on Euronext Paris.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com).

### Practical Information about Innate Pharma shares:

**ISIN code** FR0010331421  
**Ticker code** IPH

### Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

### For additional information, please contact:

**Innate Pharma**  
Laure-Hélène Mercier  
Director, Investor Relations  
Tel.: +33 (0)4 30 30 30 87  
[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

**ATCG Press**  
Marie Puvieux (France)  
Mob: +33 (0)6 10 54 36 72  
Jean-Medhi Grangeon (ROW)  
Mob: +33 (0)6 62 22 00 24  
[presse@atcg-partners.com](mailto:presse@atcg-partners.com)